REGULATORY STRATEGY OF CLINICAL DEVELOPMENT FOR FIXED COMBINATION MEDICINAL PRODUCTS
Abstract
This article is intended for specialists on drug registration and specialists in clinical trials. There are analyzed the main projects of foreign documents regulating the amount of the registration program and the program of clinical trials required to bring to market the combined drugs. Article clarifies the principal possibility for development of certain combination types and gives comprehensive information about different clinical development strategy types of fixed combination medicinal products supported with evaluation of their applicability according to intended claim of the combination. Some practical recommendations for study design selection are also given.
About the Authors
K. A. Yatsenko
Centre of Clinical Trials. Co Ltd
Russian Federation
Russian Federation
V. S. Berezina
Centre of Clinical Trials. Co Ltd
Russian Federation
Russian Federation
References
1. WHO Annex 5. Guidelines for registration of fixed-dose combination medicinal products Technical Report Series, № 929, 2005.
2. Guideline on clinical development of fixed combination medicinal products. EMA/CHMP/281825/2015.
3. Федеральный закон «Об обращении лекарственных средств» от 12.04.2010 № 61-ФЗ в редакции от 03.07.2016
4. EMA/CHMP/281825/2015/ Submission of comments on ‘Draft guideline on clinical development of fixed combination medicinal products. URL: http://www.efpia.eu/uploads/EFPIA_comments_Gdle_fixed_combination_final.doc (дата обращения 10.10.2016).
5. COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP), Questions and Answers Document on the Clinical Development of Fixed Combinations of Drugs belonging to different therapeutic classes in the field of cardiovascular treatment and prevention, CHMP/EWP/191583/2005
6. Food and Drug Administration, Fixed-Combination and Co-Packaged Drugs: Applications for Approval and Combinations of Active Ingredients Under Consideration for Inclusion in an Over-the-Counter Monograph. Federal Register. Т. 80. № 246. С. 79776 - 79795.
7. FDA CDER, Fixed Dose Combinations, Co-Packaged Drug Products, and Single-EntityVersions of Previously Approved Antiretrovirals for the Treatment of HIV. Procedural 2006.
8. EMA CHMP, Guideline on the Investigation of Drug Interactions CPMP/EWP/560/95/Rev. 1 Corr.
9. EMA CHMP, Guideline on the investigation of bioequivalence CPMP/EWP/QWP/1401/98 Rev. 1/ Corr**
Review
For citations:
Yatsenko K.A., Berezina V.S. REGULATORY STRATEGY OF CLINICAL DEVELOPMENT FOR FIXED COMBINATION MEDICINAL PRODUCTS. Drug development & registration. 2016;(4):222-228. (In Russ.)
Views:
832
Email this article 